Literature DB >> 7981210

Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals.

S An1, J Yang, S W So, L Zeng, E J Goetzl.   

Abstract

The EP3 subtype of prostaglandin E2 receptor transduces diverse physiological responses in mammalian tissues through signaling pathways coupled to heterotrimeric G proteins. Distinct cDNA clones encoding five isoforms of the EP3 receptor were isolated from a human uterus cDNA library. The human EP3 receptor isoforms designated hEP3-I, I', II, III, and IV are derived from alternative RNA splicing and differ only in the distal sequences of their carboxyl-terminal cytoplasmic tails. The unique cytoplasmic tails consist of 31 amino acids for isoforms I and I', 29 for II, 6 for III, and 15 for IV. When stably expressed in CHO cell transfectants, all isoforms exhibited similar EP3-specific binding of [3H]-PGE2 and PGE2 analogs. The EP3-selective agonist M&B 28767 both decreased the intracellular cAMP concentration ([cAMP]i) and increased the intracellular concentration of calcium ([Ca2+]i) with quantitative differences among different isoforms, but none mediated an increase in [cAMP]i. Pertussis toxin treatment completely blocked the decrease in [cAMP]i, but not the increase in [Ca2+]i evoked by M&B 28767. PGE2-induced desensitization of [3H]PGE2 binding by isoforms III and IV was rapid and transient, whereas that by isoform II was slow and persistent. Reverse transcription-PCR amplification of EP3 receptor messages in human kidney and uterine tissue RNA detected expression of all isoforms with different abundancies. The dual signal transduction pathways and distinctive tissue distribution of isoforms of the EP3 receptor are consistent with its mediation of diverse functions of PGE2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981210     DOI: 10.1021/bi00252a016

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  36 in total

1.  Identification of a region of the C-terminal domain involved in short-term desensitization of the prostaglandin EP4 receptor.

Authors:  M Bastepe; B Ashby
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 2.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  Downregulation of lipopolysaccharide-induced intercellular adhesion molecule-1 expression via EP2/EP4 receptors by prostaglandin E2 in human fibroblasts.

Authors:  K Noguchi; K Iwasaki; M Shitashige; M Umeda; Y Izumi; S Murota; I Ishikawa
Journal:  Inflammation       Date:  2001-04       Impact factor: 4.092

4.  Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation.

Authors:  Linda J Kay; Wilfred W Yeo; Peter T Peachell
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

5.  Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus.

Authors:  D Pyeon; F J Diaz; G A Splitter
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 6.  Prostaglandin E2 receptor distribution and function in the gastrointestinal tract.

Authors:  I Dey; M Lejeune; K Chadee
Journal:  Br J Pharmacol       Date:  2006-10-02       Impact factor: 8.739

7.  Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility.

Authors:  Lihong Chen; Yifei Miao; Yahua Zhang; Dou Dou; Limei Liu; Xiaoyu Tian; Guangrui Yang; Dan Pu; Xiaoyan Zhang; Jihong Kang; Yuansheng Gao; Shiqiang Wang; Matthew D Breyer; Nanping Wang; Yi Zhu; Yu Huang; Richard M Breyer; Youfei Guan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10-11       Impact factor: 8.311

8.  Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery.

Authors:  S J Lydford; K C McKechnie; I G Dougall
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

9.  The EP3 Receptor: Exploring a New Target for Type 2 Diabetes Therapeutics.

Authors:  Joshua C Neuman; Michelle E Kimple
Journal:  J Endocrinol Diabetes Obes       Date:  2013 Jul-Sep

10.  Intermolecular cross-talk between the prostaglandin E2 receptor (EP)3 of subtype and thromboxane A(2) receptor signalling in human erythroleukaemic cells.

Authors:  Helen M Reid; B Therese Kinsella
Journal:  Br J Pharmacol       Date:  2009-08-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.